Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Status:
Completed
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
This study evaluates the treatment of psoriasis with aminopterin. Participants will be
treated for 14 weeks with either aminopterin or placebo followed. The participants will not
know if they are being treated with aminopterin or placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)